main navigation
MSGPP - Home
Project Description
  Flow Diagrams
Contact Information
  Program Project Members
Target Diseases & Organisms
* Malaria
   Plasmodium falciparum
   Plasmodium vivax
* Chagas' Disease
    [American Trypanosomiasis]
   Trypanosoma cruzi
* Sleeping Sickness
    [African Trypanosomiasis]
   Trypanosoma brucei
* Leishmaniasis
   Leishmania spp.
* Amoebiasis
   Entamoeba histolytica
* Giardiasis
   Giardia lamblia
* Toxoplasmosis
   Toxoplasma gondii
* Cryptosporidiosis
   Cryptosporidium parvum
Genome Databases
Target Progress
Ligand Screening
Papers by MSGPP
Related Links/Resources
Employment Opportunities
MSGPP

AMERICAN TRYPANOSOMIASIS
Chagas' Disease (Trypanosoma cruzi)

American Trypanosomiasis (Chagas' Disease) has the potential to infect around 100 million people in twenty-one Central and South American countries. This unicellular parasite is transmitted by the Reduviid bug in rural areas or by blood transfusion. In Santa Cruz, Bolivia more than 50% of blood donors are reported to be infected. Current World Health Organization (WHO) estimates show that 16 to 18 million people are infected. Additionally, migration has brought infected persons into major world-wide cities and the United States. Like most trypanosomids, these organisms display antigenic variation and are easily resistant to drugs. The current drug treatments are toxic to humans.

Organism Trypanosoma cruzi
At Risk 100 million - Central and South America
Humans Infected 16-18 million
Disease Outcome 10-30% die of complications
after decades of infection
Vaccine Prospects Poor due to antigenic variation
Available Drugs Only one - toxic and ineffective
Drug Resistance Suspected

General information: Medline, World Health Organization